Business Daily Media

Times Advertising

.

Adlai Nortye Announces First Patient Dosed in Phase Ia Clinical Trial of AN2025 and AN0025 in Combination with atezolizumab for Advanced Solid Tumors

  • Written by ACN Newswire - Press Releases

Adlai Nortye Announces First Patient Dosed in Phase Ia Clinical Trial of AN2025 and AN0025 in Combination with atezolizumab for Advanced Solid Tumors

NEW JERSEY, the U.S. and HANGZHOU, China, Sep 8, 2021 - (ACN Newswire) - Adlai Nortye, a global biopharmaceutical company focused on developing innovative oncology drugs, today announced that the first patient has been dosed in the Phase Ia clinical trial in the U.S. to evaluate the triple combination of AN2025 (buparlisib, oral pan-PI3K

Read more //?#

Why self-service is reshaping fleet management for modern businesses

Fleet management today is constrained by fragmented systems and heavy administrative demands. A lot of the work still relies on booking vehicles and...

Fraud Prevention and security crucial as identity crime hits record highs in Australia

In a radically transformed risk landscape where the scale and speed of financial fraud have reached unprecedented levels, Australian businesses ar...

Sectorial ATO Tax Debt Disclosures Rise, Overall Business Credit Demand Flattens and High-Risk SME 'Credit Shopping' hits 8-month peak

Q1 2026 Equifax Business Market Pulse shows low-risk borrowers consolidate demand enquiries while sub-prime entities accelerate shopping activity ...

SME support in Federal Budget falls short of easing business pressures

“The Federal Budget delivered several measures aimed at supporting small businesses, including making the instant asset write-off permanent, exten...

Bunji dog treats to hit Ritchies shelves

Cooee Native Superfoods’ Bunji range of dog kibble and treats is rolling out across Ritchies Supermarkets now, with stock already on shelves in se...

Pre-Budget Expectations

“Australian corporates and SMBs are under pressure. Competition from global players is intensifying, margins are under strain, and technology adop...